Novartis Medical Affairs-Guided Medical Expert Survey

:General Questions

Q1:Which of the following best describes where ME practices?

Q2:Which of the following best describes ME’s area of specialty?

Q3:In the last month/4 weeks of ME’s outpatient clinics, what percentage of newly diagnosed patients had early breast cancer (EBC) thought to be completely resectable?

:Unmet Medical Need

Q4:Of the patients diagnosed with EBC in your practice(s) each month, what percentage of tumors are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-)?

Q5:For those patients with HR+, HER2– EBC, how often is adjuvant treatment likely offered?

:Physician/Patient Journey

Q6:Which of the following factors and/or tools do you MAINLY use to determine risk of disease recurrence and adjuvant treatment modality for patients diagnosed with HR+, HER2– EBC?

Q7:Which patient characteristic would you consider MOST important when deciding whether to initiate adjuvant treatment(s)?

Q8:Based on the patient characteristic you’ve identified in the previous question ,which of the following would you consider the MOST important part of your standard treatment approach for these patients?

Q9:[Select ALL that apply]Which patients with node-negative (N0) tumors do you intend to treat with adjuvant therapy to prevent disease progression?

Q10:In your country/region, do you have standardized screening programs to identify patients with EBC?

Q11:Which specialty in your institution initiate patients on treatment with adjuvant therapies the MOST?

Q12:What international BC guideline do you refer to the MOST when considering adjuvant treatment?

:ME Mapping

Q13:[Select ALL that apply] Have you been involved in any of the following settings to gain experience using CDK4/6 inhibitors in EBC?

Q14:Why do you think CDK4/6 inhibitors may work in the adjuvant setting?

Q15:Considering tolerability, which of the following adverse events do you consider having the MOST impact on patient adherence to CDK4/6 inhibitor treatment in the adjuvant setting?

Q16:How often have you been consulted by payers, health authorities, or peers on treatment choice/guidelines in EBC?

:Competitor Adoption

Q17:If you have used a CDK4/6 inhibitor (+ ET) in routine clinical practice in EBC (outside clinical trials), how satisfied do you think your patients have been with their treatment experience?

Q18:In your opinion, which of the following poses the greatest challenge with incorporating the currently approved CDK4/6 inhibitor + ET adjuvant therapy into your practice(s)?

Q19:When selecting a CDK4/6 inhibitor (+ ET) in EBC, which of the following has the greatest impact in your decision-making process?

Q20:When considering a CDK4/6 inhibitor (+ ET) in the EBC setting, how long do you think would be the ideal duration of treatment? Why?

Q21:Which metastatic breast cancer (mBC) treatment modality would you consider the MOST appropriate for patients who had disease recurrence 12 months after completion of adjuvant CDK4/6 inhibitor (+ ET) therapy?